A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic.
Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic. This story matters for Finance & Markets readers tracking lending. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. LendingNews curates and briefs the finance & markets stories that matter. Our editorial policy →